TABLE 9.
Representative studies related to chemotherapy for advanced liposarcoma.
| Drugs | Years of report | Study types | Setting | Number of patients | ORR | M-PFS (months) | References |
|---|---|---|---|---|---|---|---|
| Cabazitaxel 25 mg/m2/3w | 2022 | Phase II trial | 1–2 line | 38 | 8% | 6 | Sanfilippo et al. (2022) |
| Eribulin 1.4 mg/m2/d1,8/3w | 2022 | Phase IV trial | ≥2 line | 64 | 4.7% | 3.2 | Kawai et al. (2022) |
| Trabectedin 1.5 mg/m2/d1/3w | 2019 | Phase III trial | ≥2 line | 102 | 9% | 3 | Patel et al. (2019) |
| Dacarbazine 1,000 mg/m2/d1/3w | 2019 | Phase III trial | ≥2 line | 52 | 6% | 1.5 | Patel et al. (2019) |
| Gemcitabine 900 mg/m2/d1,8/3w plus docetaxel 75 mg/m2/d8/3w | 2019 | Phase II trial | Any-line | 15 | - | 5.6 | Jones et al. (2019) |
| Eribulin 1.4 mg/m2/d1,8/3w | 2017 | Phase III trial | ≥3 line | 71 | 1.4% | 2.9 | Demetri et al. (2017) |
| Dacarbazine 850–1,200 mg/m2/d1/3w | 2017 | Phase III trial | ≥2 line | 72 | 0% | 1.7 | Demetri et al. (2017) |
| Doxorubicin 75 mg/m2/d1/3w | 2012 | Phase II trial | First-line | 22 | - | 6.7 | Demetri et al. (2012) |
| Eribulin 1.4 mg/m2/d1,8/3w | 2011 | Phase II trial | ≥2 line | 37 | 3% | 2.6 | Schoffski et al. (2011) |
ORR, objective response rate; M-PFS, median progression-free survival.